http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
Bristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals
View Older Stories
-
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research So
-
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophr
-
U.S. FDA Approves Bristol Myers Squibb (BMY) and 2seventy bio’s (TSVT) Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
-
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
-
Bristol-Myers Squibb (BMY) European Commission Expands Approval of Reblozyl
-
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syn
-
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
-
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
-
Bristol-Myers Squibb (BMY) Announces KRYSTAL-12 Confirmatory Trial of KRAZATI Meets Primary Endpoint
-
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRA
-
Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
-
Bristol-Myers Squibb (BMY) Announces KRYSTAL-12 Trial of KRAZATI Met Primary Endpoint
-
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Lo
-
Bristol-Myers Squibb (BMY) Provides Update on the First Phase 3 YELLOWSTONE Trial of Oral Zeposia
-
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
-
Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
-
Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascul
-
Bristol-Myers Squibb's (BMY) Abecma Approved in EU
-
Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myel
-
Bristol-Myers Squibb (BMY) Announces CheckMate -9DW Trial of Opdivo Plus Yervoy Met Primary Endpoint
-
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocel
-
Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign
-
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
-
Bristol-Myers Squibb (BMY) Completes Acquisition of Karuna Therapeutics (KRTX)
-
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
-
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
-
Bristol-Myers Squibb (BMY) FDA Approves Breyanzi for Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
-
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (
-
Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024
-
Bristol-Myers Squibb (BMY) Announces FDA Approval of Opdivo in Combination with Cisplatin and Gemcitabine
-
U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Ca
-
Bristol Myers Squibb Announces Dividend
-
Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
-
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
-
Bristol Myers Squibb to Participate in the TD Cowen 44th Annual Health Care Conference
-
Bristol-Myers Squibb (BMY) Completes Acquisition of RayzeBio (RYZB)
-
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
-
Bristol-Myers Squibb (BMY) Announces Expiration of Tender Offer for RayzeBio
-
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Reblozyl
-
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
-
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (
-
Immunocore (IMCR) announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab
-
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first
-
Bristol-Myers Squibb (BMY) Announces FDA Acceptance of sBLA for KRAZATI in Combination with Cetuximab
-
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Tr
-
Bristol-Myers Squibb (BMY) Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC
-
Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC
-
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
-
Bristol-Myers Squibb (BMY) Announces FDA Acceptance for Priority of Application for Augtyro
-
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or M
